Purdue's Sacklers boost opioid settlement offer up to $6 billion

As part of the deal, Purdue will hand over nearly all of its assets to the states, cities and counties that are suing the drugmaker over its handling of the pain killer OxyContin

Purdue Pharma
As part of the deal, Purdue will hand over nearly all of its assets to the states, cities and counties that are suing the drugmaker over its handling of the pain killer OxyContin
Bloomberg
3 min read Last Updated : Feb 19 2022 | 2:50 PM IST
Members of the billionaire Sackler family that own Purdue Pharma LP have offered to pay as much as $6 billion to revive the OxyContin maker’s imperiled opioid settlement, a more-than $1 billion increase from their existing proposal.

The new settlement offer would see the Sackler family pay at least $5.5 billion, with additional money contingent on certain asset sales, a court appointed mediator, U.S. Bankruptcy Judge Shelley Chapman, said in a report Friday. A final deal hasn’t been reached, according to the mediator.

The Sacklers and a handful of state attorneys general have been in mediation for the past two months, after a New York judge rejected an earlier deal negotiated as part of the company’s bankruptcy. That settlement would have resolved trillions of dollars in claims by state and local governments over the company’s role in the opioid crisis and give Sackler family members broad immunity from future lawsuits. 

As part of the deal, Purdue will hand over nearly all of its assets to the states, cities and counties that are suing the drugmaker over its handling of the pain killer OxyContin. Billions of dollars also would be provided to fund anti-addiction programs. 

But the plan to give Purdue’s owners immunity from future opioid lawsuits has been a sticking point, drawing the ire of some states and local politicians. Attorneys general from eight states and the District of Columbia, along with an arm of the U.S. Justice Department, succeeded in having the settlement overturned on appeal after Purdue’s bankruptcy judge approved it last year.

More Support

Most, but not all, of the dissenting states have agreed to the new settlement offer, according to mediator’s report. The Sacklers’ offer is contingent on unanimous support, the report says.

“We remain focused on achieving our goal of providing urgently needed funds to the American people for opioid crisis abatement,” Michele Sharp, a Purdue spokeswoman, said in an email. “We believe a global settlement is the swiftest and most cost-effective exit path from Chapter 11 and we will continue working to build consensus as we proceed through the appeal process with the United States Court of Appeals for the Second Circuit.”

Connecticut Attorney General William Tong, who was among those who opposed the earlier offer, declined to comment Friday on the mediator’s report. Representatives of Maryland Attorney General Brian Frosh didn’t immediately return an email seeking comment. 

Representatives for the Mortimer Sackler and Raymond Sackler wings of the family didn’t immediately respond to requests for comment.

Chapman requested the court-ordered mediation be extended to Feb. 28. The previous order lapsed on Wednesday. 

The bankruptcy case is Purdue Pharma LP, 19-23649, U.S. Bankruptcy Court for the Southern District of New York (White Plains).

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :PharmaceuticalPharma Companiespainkiller

Next Story